FDA Data Reveals Potential Link Between GLP-1 Drugs and Male Sexual Dysfunction
Analysis of FDA adverse event reports found signals of erectile dysfunction, decreased libido, and orgasmic dysfunction associated with multiple GLP-1 drugs.
Quick Facts
What This Study Found
FAERS disproportionality analysis found signals of male sexual dysfunction (ED, decreased libido, orgasmic dysfunction) associated with GLP-1 receptor agonists.
Key Numbers
182 cases total; exenatide 24.2%, semaglutide 21.4%; ages 40-60 predominant; ROR 0.41 (below 1); chi-squared P<0.0001 but low ROR indicates no disproportionate signal.
How They Did This
Cross-sectional pharmacovigilance analysis of FAERS data (Q4 2003 – Q1 2024) using OpenVigil 2.1 with disproportionality measures.
Why This Research Matters
With millions of men taking GLP-1 drugs, even uncommon sexual side effects affect a large absolute number of patients.
The Bigger Picture
As GLP-1 drug use expands rapidly, pharmacovigilance studies like this help build a more complete picture of real-world side effects.
What This Study Doesn't Tell Us
FAERS data is spontaneous reporting — cannot establish causation, incidence rates, or control for confounders like obesity and diabetes themselves.
Questions This Raises
- ?Is the sexual dysfunction caused by the drug, the weight loss, or underlying conditions?
- ?Do specific GLP-1 drugs have higher risk than others?
Trust & Context
- Key Stat:
- 6 GLP-1 drugs FAERS analysis covering tirzepatide, semaglutide, dulaglutide, exenatide, lixisenatide, and liraglutide
- Evidence Grade:
- Pharmacovigilance signal detection — useful for hypothesis generation but cannot prove causation due to reporting biases.
- Study Age:
- Published in 2025, covering 20 years of adverse event reports through early 2024.
- Original Title:
- Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data.
- Published In:
- International journal of impotence research, 37(8), 661-667 (2025)
- Authors:
- Pourabhari Langroudi, Ashkan, Chen, Abby L, Basran, Satvir, Sommer, Elijah R, Stinson, James, Cheng, Yu-Sheng, Del Giuduce, Francesco, Scott, Michael, Eisenberg, Michael L
- Database ID:
- RPEP-13096
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs affect sexual function in men?
FDA adverse event data shows reporting signals for ED, low libido, and orgasmic dysfunction, but a direct causal link has not been established.
Should I stop my GLP-1 drug if I have sexual problems?
Discuss any new symptoms with your doctor. Sexual dysfunction can have many causes including the underlying conditions these drugs treat.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13096APA
Pourabhari Langroudi, Ashkan; Chen, Abby L; Basran, Satvir; Sommer, Elijah R; Stinson, James; Cheng, Yu-Sheng; Del Giuduce, Francesco; Scott, Michael; Eisenberg, Michael L. (2025). Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data.. International journal of impotence research, 37(8), 661-667. https://doi.org/10.1038/s41443-025-01061-2
MLA
Pourabhari Langroudi, Ashkan, et al. "Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data.." International journal of impotence research, 2025. https://doi.org/10.1038/s41443-025-01061-2
RethinkPeptides
RethinkPeptides Research Database. "Male sexual dysfunction associated with GLP-1 receptor agoni..." RPEP-13096. Retrieved from https://rethinkpeptides.com/research/pourabhari-2025-male-sexual-dysfunction-associated
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.